The treatment landscape for resectable early-stage melanoma has seen an exciting shift with use of adjuvant immunotherapy. Engaging patients in shared-decision making is key for optimizing treatment outcomes. In this interactive case-based challenge, enhance your knowledge and test your skills in applying patient- and disease-specific factors to guide biomarker-directed treatment selection. Don’t miss the evidence-based strategies for shared-decision making and a downloadable summary of key supporting evidence to guide your practice in managing patients with early-stage melanoma.Through this educational activity, you have the opportunity to earn a maximum of 2.5 CE credits in total. To achieve this, you can complete the PRIME clinical case challenge to earn 0.25 CE credits. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn an extra 2.25 CE credits. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation.Total Possible Credits: 2.5 CE Credits from PRIME Clinical Case Challenge: 0.25 CE Credits from SynopsiMedEd Related Evidence: 2.25 CE This activity is delivered in partnership with the Melanoma Research Alliance.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/individualizing-treatment-selection-planning-early-stage-melanoma
- Start Date: 2024-07-25 05:00:00
- End Date: 2024-07-25 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 2.5 hours
AMA PRA Category 1 Credit™️: 2.5 hours
Nursing: 2.5 hours
Pharmacy: 2.5 hours - Commercial Support: Source: Merck (Any division) - Amount: 33333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all